Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma
Yanyan Han 1* , Ran Tao 2 , Jin Huang 3 , Yabing Guo 3 , Dongyun Wu 2 , Yujing Liao 3 , Jin Li 2 , Xiangjun Zhou 2 , Jinlin Hou 3
From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014 Background Hepatocellular carcinoma (HCC) is one of the most common tumors in China, and frequently occurs in patients with chronic hepatitis B virus (HBV) infection. Although liver resection and other therapies may improve survival, HCC is rarely cured and with high risk of recurrence and metastasis. Here we present a practical adoptive immunotherapy named "Smart T" to prepare multiple tumor antigens activated T lymphocytes ex vivo, with a promising outcome in a preliminary clinical applications with HCC patients.
Methods
Auotologous T cells from HCC patients were stimulated with mature DCs pulsed with multiple synthetic HCC-antigen peptides pool. The resulting T cells were infused into patients every 2-3 months with 5-10x10 7 cells/ kg body weight for multiple cycles.
Results
The resulting cells are mainly polyfunctional T cells (95% ± 1%) co-expressing INF-γ, TNFα and Granzyme B. The activated T cells generated from HLA-A2 + patient exhibited greater cytotoxic activity to the HLA-A2 + HCC cells than to the HLA-A2 -HCC cells. Up to date, 138 HCC patients have received "Smart T" treatments. No toxicity was observed. After 3 cycles of "Smart T" treatments, we have detected a significant increase of CD8 + CD107a + T cells (p = 0.0082), effector T cells (p = 0.0013) and central memory T cells (p = 0.0038) in the patients' PBMCs as well as a 1 SYZ Cell Therapy Co., & Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Peoples Republic of China Full list of author information is available at the end of the article Figure 1 significant decrease of regulatory T cells (p = 0.0015). Specific proliferation and IFN-γ production of T cells stimulated by HCC-antigens pool was also detected in the HCC patients' PBMCs as compared to irrelevant antigen stimulation (Figure 1) . Moreover, the IFN-γ ELISPOT assay ( Figure 2 ) demonstrated specific responses in patients against each kind of peptides, most of them responded to carcinoembryonic antigen (CEA), survivin, vascular endothelial growth factor receptor (VEGFR), alpha fetoprotein (AFP), glypican-3 (GPC3), HBV core antigen and HBV DNA polymerase. A retrospectively clinical analysis revealed that after multiple "Smart T" treatments, the recurrence and metastasis incidence in one year was low to 10% in the patients with B stage of HCC (n = 10), compared to B stage HCC patients without "Smart T" treatment (n = 14, recurrence and metastasis incidence: 71%, p = 0.005, analyzed by Fisher's exact 2-sided test).
Conclusion
Our study, for the first time, demonstrates tumor antigens specific T cell responses can be robustly raised in HCC patients after Smart T treatment, and provides a safe treatment which may improve the immunologic function and clinical outcome of the HCC patients.
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